Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Update

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totaling 25,732 shares, a drop of 58.6% from the August 31st total of 62,228 shares. Based on an average daily trading volume, of 500 shares, the short-interest ratio is presently 51.5 days.

Wall Street Analyst Weigh In

Separately, Danske began coverage on shares of Hansa Biopharma AB (publ) in a research note on Tuesday, June 16th. They set a “buy” rating for the company. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy”.

Hansa Biopharma AB (publ) Price Performance

Hansa Biopharma AB (publ) stock remained flat at $3.70 during midday trading on Monday. Hansa Biopharma AB has a 52-week low of $2.90 and a 52-week high of $3.70. The stock’s 50 day moving average is $3.57 and its 200-day moving average is $3.14.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a Swedish biotechnology company focused on developing and commercializing treatments for rare immunological conditions. The company’s technology is designed to selectively modulate the immune system, with the goal of enabling medical procedures and addressing diseases in which pathogenic antibodies play a significant role.

Its leading product is Idefirix (imlifidase), an enzyme therapy that rapidly cleaves immunoglobulin G antibodies. Idefirix is approved in the European Union for desensitization treatment of highly sensitized adult kidney transplant patients who are unlikely to receive a transplant under the available kidney allocation system.